STOCK TITAN

Electromed - ELMD STOCK NEWS

Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.

About Electromed, Inc. (ELMD)

Electromed, Inc., headquartered in Minnesota, is a prominent player in the respiratory care industry, specializing in the development, manufacturing, and global distribution of innovative airway clearance therapy solutions. The company’s flagship product, the SmartVest® Airway Clearance System, utilizes advanced high-frequency chest wall oscillation (HFCWO) technology to provide a clinically proven, non-invasive alternative to traditional chest physiotherapy (CPT). This technology is designed to help patients with compromised pulmonary function clear excess mucus from their lungs, reducing the risk of infections and improving overall respiratory health.

Core Business and Products

At the heart of Electromed’s operations is the SmartVest System, which consists of a programmable air pulse generator, a wearable therapy garment, and a connecting hose. Together, these components deliver safe, comfortable, and effective airway clearance therapy. The system is particularly beneficial for individuals suffering from chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, atelectasis, and various neuromuscular diseases. By addressing the challenges of retained secretions, the SmartVest System enhances patients’ quality of life and reduces the frequency of hospitalizations related to respiratory complications.

Industry Position and Differentiation

Electromed operates in the highly specialized respiratory care market, where regulatory compliance, clinical efficacy, and patient comfort are paramount. The company distinguishes itself through its commitment to innovation, quality, and compassionate service. Its products are accredited by the Joint Commission and certified under ISO 13485:2003 and ISO 9001:2008 standards, underscoring its adherence to rigorous quality management systems. Additionally, the patented HFCWO technology provides a competitive edge by offering a more tolerable and effective solution compared to traditional CPT methods.

Business Model and Revenue Streams

Electromed generates revenue primarily through the direct sale of its SmartVest System and related accessories. The company also benefits from recurring revenue streams, which may include replacement parts, service agreements, and ongoing support for its devices. Its focus on patient-centric care and long-term relationships with healthcare providers further strengthens its market position.

Regulatory and Clinical Excellence

Operating within the medical device industry, Electromed is subject to stringent regulatory requirements. Its accreditation and ISO certifications reflect its dedication to maintaining high standards of safety and efficacy. The company’s products are backed by clinical research demonstrating their effectiveness in clearing mucus, reducing lung infections, and improving respiratory function. This evidence-based approach enhances its credibility among healthcare professionals and patients alike.

Market Significance

The respiratory care market continues to grow due to an aging population and the increasing prevalence of chronic respiratory conditions. Electromed’s innovative solutions address a critical need within this market, positioning the company as a key contributor to improving pulmonary health outcomes. By focusing on both technological advancement and patient well-being, Electromed has carved out a niche in the competitive landscape of airway clearance therapy.

Commitment to Patients and Healthcare Providers

Electromed’s mission extends beyond product development to include a strong emphasis on compassionate service and patient education. The company works closely with healthcare providers to ensure that its solutions are effectively integrated into treatment plans, empowering patients to manage their conditions more effectively. This holistic approach reinforces Electromed’s reputation as a trusted partner in respiratory care.

Rhea-AI Summary
Electromed, Inc. has launched the SmartVest Clearway Airway Clearance System for inpatient use in hospitals. The system uses High Frequency Chest Wall Oscillation therapy to clear excess secretions from the lungs and reduce the risk of respiratory infections. It provides therapeutic relief for patients with ineffective secretion clearance and aims to speed up patient recovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
Rhea-AI Summary
Electromed, Inc. announced that its President and CEO, Jim Cunniff, and CFO, Brad Nagel, will attend the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 16, 2023 in New York City. The management team will engage in investor 1x1s on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary
Electromed, Inc. will release its financial results for the fiscal 2024 first quarter on November 7, 2023. A conference call will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Electromed, Inc. announces record annual revenue and Q4 revenue growth of 21%. FY 2023 revenue increased 15% to $48.1 million. Operating income increased 35% to $4.0 million. Net income increased to $3.2 million, or $0.36 per diluted share. Cash as of June 30, 2023, was $7.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.02%
Tags
Rhea-AI Summary

Electromed, a leader in airway clearance technologies (NYSE American: ELMD), announced the participation of Kathleen Skarvan, President and CEO, and Brad Nagel, CFO, at the Inaugural EF Hutton Global Conference in New York City on May 10-11, 2023. The management team will hold one-on-one meetings on May 11, 2023, providing an opportunity for investors to learn more about Electromed's innovative airway clearance solutions, including the SmartVest® Airway Clearance System. Founded in 1992 and headquartered in New Prague, Minnesota, Electromed focuses on products that assist patients with compromised pulmonary function. For more details, visit www.smartvest.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences

FAQ

What is the current stock price of Electromed (ELMD)?

The current stock price of Electromed (ELMD) is $26.18 as of March 3, 2025.

What is the market cap of Electromed (ELMD)?

The market cap of Electromed (ELMD) is approximately 229.0M.

What does Electromed, Inc. specialize in?

Electromed, Inc. specializes in developing and manufacturing airway clearance therapy solutions, including the SmartVest® Airway Clearance System, which utilizes high-frequency chest wall oscillation (HFCWO) technology.

What is the SmartVest® Airway Clearance System?

The SmartVest System is a medical device that helps patients with compromised pulmonary function clear mucus from their lungs using high-frequency chest wall oscillation (HFCWO) technology.

Which conditions does Electromed’s SmartVest System treat?

The SmartVest System is designed to treat conditions such as COPD, bronchiectasis, cystic fibrosis, atelectasis, and various neuromuscular diseases by improving airway clearance and reducing lung infections.

How does Electromed differentiate itself in the respiratory care market?

Electromed differentiates itself through its patented HFCWO technology, rigorous quality standards, ISO certifications, and a strong focus on patient comfort and clinical efficacy.

What is high-frequency chest wall oscillation (HFCWO)?

HFCWO is a non-invasive therapy that uses oscillating air pressure to loosen and mobilize mucus in the lungs, making it easier for patients to clear their airways.

What regulatory certifications does Electromed hold?

Electromed is accredited by the Joint Commission and certified under ISO 13485:2003 and ISO 9001:2008, reflecting its commitment to quality and safety in medical device manufacturing.

Who are Electromed’s primary customers?

Electromed primarily serves patients with chronic respiratory conditions, healthcare providers, and medical facilities focused on pulmonary care.

What is the significance of Electromed’s ISO certifications?

The ISO certifications demonstrate Electromed’s adherence to international quality management standards, ensuring the safety and reliability of its medical devices.
Electromed

NYSE:ELMD

ELMD Rankings

ELMD Stock Data

228.98M
6.76M
27.77%
36.07%
1.73%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
NEW PRAGUE